MedTrace Logo

Study Regarding the Clinical Efficacy of Synatura® in Patients With Chronic Bronchitis Type COPD

NCT03623282 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-08-10

No results posted yet for this study

Summary

This study aims to examine the clinical efficacy of synatura in patients with chronic bronchitis type COPD in Korea.

Conditions

  • Bronchitis, COPD

Interventions

DRUG

Synatura® 15 mL

All subjects will receive Synatura® 15 mL every day three times for 3 months.

Sponsors & Collaborators

  • Ahn-Gook Pharmaceuticals Co.,Ltd

    lead INDUSTRY

Principal Investigators

  • Chinkook Rhee, MD · Seoul St. Mary's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-17
Primary Completion
2018-05-02
Completion
2018-05-02

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03623282 on ClinicalTrials.gov